Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 306

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials

Open access
Vergote, Ignace, Coens, Corneel, Nankivell, Matthew, Kristensen, Gunnar B, Parmar, Mahesh K B, Ehlen, Tom, Jayson, Gordon C, Johnson, Nick, Swart, Ann Marie, Verheijen, René, McCluggage, W Glenn, Perren, Tim, Panici, Pierluigi Benedetti, Kenter, Gemma, Casado, Antonio, Mendiola, Cesar, Stuart, Gavin, Reed, Nick S, Kehoe, Sean, Tropé G., Claes, Dobbs, Stephen, Essapen, Sharadah, Hoskins, P., Green, John, Gilby, E., Van Baal, M., Twigg, Jeremy, Van Der Burg, Maria E.L., Godfrey, Keith, Lacave, Angel J., Angioli, R., Nath, Rahul, Chin, Kirk, Redman, Charles, Lotocki, R., Olaitan, Adeola, Mosgaard, B., Rustin, G., Ind, Thomas, Persic, Mojca, Hogg, Martin, Van Der Velden, J., Ledermann, J., Peter Sykes, Peter Sykes, Madhavan, Krishnawam, Kannisto, P., Hird, Vicky, Evans, A., Sandvei R., R., Gauthier, P., Cruickshank, D.J., Ottevanger, P.B., Pearson, Sheila, Kitchener, Henry, Hall, Marcia, Bessette, P., Pecorelli, S., Gerdin, E., Lopes, Tito, Fish, Andrew, Barlow., Clare, Van Eygen, K., Floquet, A., Tholander, B., Gul, N., Gornall, Robert, Luesley, David, Kirwan, Philip, Symonds, Paul, Henry, Richard, Poole, David, McNeish, Ian, Hocking, Mark, Sammaraie, Al, Speiser, P., Leblanc, E., Green, J.A., De Oliveira, C.F., Grimshaw, R., Zola, P., Parkin, David, Luesley, David, Lamb, Martin, Hong, Anne, Gillespie, Alan, Hamid, Abdel, Ahmed, Ahmed, Plante, M., De Valk, B., Nordin, A., Clamp, Andrew, Perez, David, Graham Dark, Graham Dark, Ferguson, Michelle, MacGregor, Carol, Skailes, Geraldine, Jones, Rachel, Gillespie, Alan, Cawdell, G., Leeson, Simon, Elit, L., Dittrich, C., Gotlieb, W., Poole, David, Cullimore, John, Crosse, Barbara, Ridley, Paul, Head, Anthony, Nieto, Joaquin, Awwad, Saif, Brinkmann, Dirk, Eustace, Damian, Hindley, Andrew, Katsaros, D., Popadiuk, C., Kristeller, Tome, Redman, C., Chan, S., Marth, C., Yiannakis, Dennis, Lankaster, Kate, Beynon, Gareth, Suhail, Anwar, Indrajit, Fernando, Hong, Anne, Quigley, Mary, Adeyemi, Olu, Persic, Mojca, Lofts, Fiona, McNally, Orla, Tristam, Amanda, Lee, Martin, Counsell, R., Gleeson, N., Papadopoulos, A., Maggino, T., Honkoop, A., Ghatage, P., Vermorken, J.B., De Greve, J., Boman, K., Petru, E, Amant, F.·2018·The Lancet Oncology

Abstract

BACKGROUND Individual patient data from two randomised trials comparing neoadjuvant chemotherapy with upfront debulking surgery in advanced tubo-ovarian cancer were analysed to examine long-term outcomes for patients and to identify any preferable therapeutic approaches for subgroup populations. METHODS We did a per-protocol pooled analysis of individual patient data from the European Organisation for Research and Treatment of Cancer (EORTC) 55971 trial (NCT00003636) and the Medical Research Council Chemotherapy Or Upfront Surgery (CHORUS) trial (ISRCTN74802813). In the EORTC trial, eligible women had biopsy-proven International Federation of Gynecology and Obstetrics (FIGO) stage IIIC or IV invasive epithelial tubo-ovarian carcinoma. In the CHORUS trial, inclusion criteria were similar to those of the EORTC trial, and women with apparent FIGO stage IIIA and IIIB disease were also eligible. The main aim of the pooled analysis was to show non-inferiority in overall survival with neoadjuvant chemotherapy compared with upfront debulking surgery, using the reverse Kaplan-Meier method. Tests for heterogeneity were based on Cochran's Q heterogeneity statistic. FINDINGS Data for 1220 women were included in the pooled analysis, 670 from the EORTC trial and 550 from the CHORUS trial. 612 women were randomly allocated to receive upfront debulking surgery and 608 to receive neoadjuvant chemotherapy. Median follow-up was 7·6 years (IQR 6·0-9·6; EORTC, 9·2 years [IQR 7·3-10·4]; CHORUS, 5·9 years [IQR 4·3-7·4]). Median age was 63 years (IQR 56-71) and median size of the largest metastatic tumour at diagnosis was 8 cm (IQR 4·8-13·0). 55 (5%) women had FIGO stage II-IIIB disease, 831 (68%) had stage IIIC disease, and 230 (19%) had stage IV disease, with staging data missing for 104 (9%) women. In the entire population, no difference in median overall survival was noted between patients who underwent neoadjuvant chemotherapy and upfront debulking surgery (27·6 months [IQR 14·1-51·3] and 26·9 months [12·7-50·1], respectively; hazard ratio [HR] 0·97, 95% CI 0·86-1·09; p=0·586). Median overall survival for EORTC and CHORUS patients was significantly different at 30·2 months (IQR 15·7-53·7) and 23·6 months (10·5-46·9), respectively (HR 1·20, 95% CI 1·06-1·36; p=0·004), but was not heterogeneous (Cochran's Q, p=0·17). Women with stage IV disease had significantly better outcomes with neoadjuvant chemotherapy compared with upfront debulking surgery (median overall survival 24·3 months [IQR 14·1-47·6] and 21·2 months [10·0-36·4], respectively; HR 0·76, 95% CI 0·58-1·00; p=0·048; median progression-free survival 10·6 months [7·9-15·0] and 9·7 months [5·2-13·2], respectively; HR 0·77, 95% CI 0·59-1·00; p=0·049). INTERPRETATION Long-term follow-up data substantiate previous results showing that neoadjuvant chemotherapy and upfront debulking surgery result in similar overall survival in advanced tubo-ovarian cancer, with better survival in women with stage IV disease with neoadjuvant chemotherapy. This pooled analysis, with long-term follow-up, shows that neoadjuvant chemotherapy is a valuable treatment option for patients with stage IIIC-IV tubo-ovarian cancer, particularly in patients with a high tumour burden at presentation or poor performance status. FUNDING National Cancer Institute and Vlaamse Liga tegen kanker (Flemish League against Cancer).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(18)30566-7

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Cited by

See all 306

Metadata

Authors
Vergote, I., Coens, C., Nankivell, M., Kristensen, G. B., Parmar, M. K. B., Ehlen, T., Jayson, G. C., Johnson, N., Swart, A. M., Verheijen, R., McCluggage, W. G., Perren, T., Panici, P. B., Kenter, G., Casado, A., Mendiola, C., Stuart, G., Reed, N. S., Kehoe, S., Tropé G., C., Dobbs, S., Essapen, S., Hoskins, P., Green, J., Gilby, E., Van Baal, M., Twigg, J., Van Der Burg, M. E. L., Godfrey, K., Lacave, A. J., Angioli, R., Nath, R., Chin, K., Redman, C., Lotocki, R., Olaitan, A., Mosgaard, B., Rustin, G., Ind, T., Persic, M., Hogg, M., Van Der Velden, J., Ledermann, J., Peter Sykes, P. S., Madhavan, K., Kannisto, P., Hird, V., Evans, A., Sandvei R., R., Gauthier, P., Cruickshank, D. J., Ottevanger, P. B., Pearson, S., Kitchener, H., Hall, M., Bessette, P., Pecorelli, S., Gerdin, E., Lopes, T., Fish, A., Barlow., C., Van Eygen, K., Floquet, A., Tholander, B., Gul, N., Gornall, R., Luesley, D., Kirwan, P., Symonds, P., Henry, R., Poole, D., McNeish, I., Hocking, M., Sammaraie, A., Speiser, P., Leblanc, E., Green, J. A., De Oliveira, C. F., Grimshaw, R., Zola, P., Parkin, D., Luesley, D., Lamb, M., Hong, A., Gillespie, A., Hamid, A., Ahmed, A., Plante, M., De Valk, B., Nordin, A., Clamp, A., Perez, D., Graham Dark, G. D., Ferguson, M., MacGregor, C., Skailes, G., Jones, R., Gillespie, A., Cawdell, G., Leeson, S., Elit, L., Dittrich, C., Gotlieb, W., Poole, D., Cullimore, J., Crosse, B., Ridley, P., Head, A., Nieto, J., Awwad, S., Brinkmann, D., Eustace, D., Hindley, A., Katsaros, D., Popadiuk, C., Kristeller, T., Redman, C., Chan, S., Marth, C., Yiannakis, D., Lankaster, K., Beynon, G., Suhail, A., Indrajit, F., Hong, A., Quigley, M., Adeyemi, O., Persic, M., Lofts, F., McNally, O., Tristam, A., Lee, M., Counsell, R., Gleeson, N., Papadopoulos, A., Maggino, T., Honkoop, A., Ghatage, P., Vermorken, J. B., De Greve, J., Boman, K., Petru, E., & Amant, F.
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2018-12
Volume
19
Issue
12
Pages
1680-1687
ISSN
1470-2045 (ISSN-L)
OpenAlex
W2900298813
Cited by
306
References
18
FWCI
24.25
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. https://app.cochat.ai/papers/10.1016/s1470-2045(18)30566-7
The paper
Vergote, I., Coens, C., Nankivell, M., Kristensen, G. B., Parmar, M. K. B., Ehlen, T., Jayson, G. C., Johnson, N., Swart, A. M., Verheijen, R., McCluggage, W. G., Perren, T., Panici, P. B., Kenter, G., Casado, A., Mendiola, C., Stuart, G., Reed, N. S., Kehoe, S., . . . Amant, F. (2018). Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(18)30566-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.